IGIV-10% Infused Intravenously And Subcutaneously To Subjects With Primary Immunodeficiency Diseases - Comparison Of Pharmacokinetic Properties

被引：0
|
作者：
Leibl, H. [1 ]
Engl, W. [1 ]
Melamed, I. [2 ]
Stein, M. [6 ]
Wasserman, R. L. [3 ]
Berger, M. [4 ]
Schiff, R. I. [5 ]
机构：
[1] Baxter Innovat GMBH, Vienna, Austria
[2] First Allergy & Clin Res Ctr, Centennial, CO USA
[3] Pediat Allergy Immunol Associates, Dallas, TX USA
[4] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[5] Baxter Healthcare, Westlake Village, CA USA
[6] Allergy Associates Palm Beaches, N Palm Beach, FL USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2009年 / 123卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2008.12.052
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
25
引用
收藏
页码：S11 / S11
页数：1
相关论文
共 15 条
  • [1] IGIV 10%, Infused Intravenously, and Subcutaneously to Subjects With Primary Immunodeficiency Diseases-Efficacy, Tolerability, and Pharmacokinetic Comparison
    Schiff, R. I.
    Leibl, H.
    Wasserman, R. L.
    Stein, M.
    Melamed, I.
    CLINICAL IMMUNOLOGY, 2010, 135 (02) : 323 - 323
  • [2] Pharmacokinetic properties of Gammagard Liquid 10% (KIOVIG) administered intravenously and subcutaneously to patients with primary immunodeficiency diseases (PID)
    Schiff, R., I
    Leibl, H.
    Engl, W.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 154 : 132 - 132
  • [3] Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)
    Leibl, H.
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Engl, W.
    Schiff, R. I.
    Gelmont, D.
    Grossman, W. J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB17 - AB17
  • [4] Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)
    Schiff, R. I.
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Grossman, W. J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB15 - AB15
  • [5] PHARMACOKINETICS OF HUMAN IMMUNOGLOBULIN G, 10%, ADMINISTERED INTRAVENOUSLY (IGIV), SUBCUTANEOUSLY (IGSC) OR FACILITATED SUBCUTANEOUSLY WITH RECOMBINANT HUMAN HYALURONIDASE (IGHY): SUBSET OF PATIENTS WITH PRIMARY IMMUNODEFICIENCY
    Stein, M.
    Wasserman, R. L.
    Melamed, I.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 156 - 157
  • [6] Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in Patients with Primary Immunodeficiency (PI)
    Wasserman, Richard
    Melamed, Isaac
    Stein, Mark
    Rubinstein, Arye
    Puck, Jennifer
    Gupta, Sudhir
    Engl, Werner
    Leibl, Heinz
    Gelmont, David
    Schiff, Richard
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 367 - 367
  • [7] PHARMACOKINETICS (PK) OF HUMAN IMMUNOGLOBULIN 10% (IGG) ADMINISTERED INTRAVENOUSLY (IGIV), SUBCUTANEOUSLY (IGSC) OR FACILITATED SUBCUTANEOUSLY WITH RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISEASE (PIDD)
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Rubinstein, A.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Gelmont, D.
    Schiff, R. I.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A94 - A94
  • [8] Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)
    Stein, M.
    Wasserman, R. L.
    Melamed, I.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB14 - AB14
  • [9] Efficacy Analysis of Subcutaneous Immune Globulin (HUMAN), 10 % (SCIG 10 %) Administered Intravenously or Subcutaneously in Patients with Primary Immunodeficiency Diseases (PIDD)
    Wasserman, Richard L.
    Kobrynski, Lisa
    Stein, Mark
    Engl, Werner
    Berner, Todd
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 : S55 - S55
  • [10] PHARMACOKINETICS OF HUMAN IMMUNOGLOBULIN G, 10%, ADMINISTERED INTRAVENOUSLY (IGIV), SUBCUTANEOUSLY (IGSC) OR FACILITATED SUBCUTANEOUSLY WITH RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Rubinstein, A.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 136 - 136
12